Generalizability of clinical trials for alcohol dependence to community samples.
paper
Cited
Public
Unavailable
- Authors
- Blanco, Carlos; Olfson, Mark; Okuda, Mayumi; Nunes, Edward V; Liu, Shang-Min; Hasin, Deborah S
- Year
- 2008
- Journal
- Drug and alcohol dependence
- PMID
- 18579319
- DOI
- 10.1016/j.drugalcdep.2008.05.002
- PMCID
- PMC3755733
There is a growing concern that results of tightly controlled clinical trials of individuals with alcohol use disorders may not generalize to broader community samples. To assess the proportion of community-dwelling adults with alcohol dependence who would have been eligible for a typical alcohol dependence treatment study, we developed a new, simple method: we applied a standard set of eligibility criteria commonly used in alcohol outcome studies to a large (n=43,093) representative US adult sample interviewed face-to-face, the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). We found that approximately one-half (50.5%) of all individuals with a DSM-IV diagnosis of alcohol dependence (n=1484) and 79.4% of those who sought treatment (n=185) were excluded by one or more study criteria. Individual study criteria excluded from 0.9% to 48.2% of the overall sample and 0.8% to 43.7% of the treatment-seeking sample. For the overall sample, the lack of motivation/compliance and financial situation criteria excluded the largest percentage of individuals. In the treatment-seeking subsample, comorbid medical conditions and legal problems excluded the largest proportions of individuals. Our study provides a new method to assess the generalizability of clinical trials, and gives further evidence that typical clinical trials for alcohol dependence likely exclude most adults with the disorder in the community and under care, and support the notion that clinical trials recruit "pure" rather than "typical" patients. Clinical trials should carefully evaluate the effects of the selected eligibility criteria on the generalizability of their results.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Polygenic Risk Score Prediction of Alcohol Dependence Symptoms Across Population-Based and Clinically Ascertained Samples. | 2018 | 29405378 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| High in the Cloud: Alcohol-, Cannabis-, and Co-Use Before and During Remote Research Participation. | Hone LSE et al. | — | 2025 | → |
| Insights into Overlapping Brain Networks for Anxiety and Alcohol Use Disorders. | Zabik NL et al. | — | 2025 | → |
| Eligibility for Substance Use Clinical Trials Among Emergency Psychiatry Patients: The Impact of Exclusion Criteria. | Lawrence RE et al. | — | 2024 | → |
| Emotional dysregulation in relation to substance use and behavioral addictions: Findings from five separate meta-analyses. | González-Roz A et al. | — | 2024 | → |
| Alcohol and the Etiology of Depression. | Nunes EV | — | 2023 | → |
| Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. | Cook RR et al. | — | 2023 | → |
| Threats to external validity in the neuroprediction of substance use treatment outcomes. | Gancz NN et al. | — | 2023 | → |
| Clinicians' Perceptions of Rapid Scale-up of Telehealth Services in Outpatient Mental Health Treatment. | Sugarman DE et al. | — | 2021 | → |
| Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers. | Grodin EN et al. | — | 2021 | → |
| Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. | Ray LA et al. | — | 2021 | → |
| Examination of exclusion criteria in total knee arthroplasty rehabilitation trials: influence on the application of evidence in day-to-day practice. | Kittelson AJ et al. | — | 2021 | → |
| Generalizability of pharmacologic and psychotherapy trial results for late-life unipolar depression. | Hoertel N et al. | — | 2021 | → |
| The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population. | Aharonovich E et al. | — | 2021 | → |
| Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications. | Venegas A et al. | — | 2020 | → |
| Target validity: Bringing treatment of external validity in line with internal validity. | Lesko CR et al. | — | 2020 | → |
| Association between smoking, and hospital readmission among inpatients with psychiatric illness at an academic inpatient psychiatric facility, 2000-2015. | Kagabo R et al. | — | 2019 | → |
| Estimation of Population Average Treatment Effects in the FIRST Trial: Application of a Propensity Score-Based Stratification Approach. | Chung JW et al. | — | 2018 | → |
| Polygenic Risk Score Prediction of Alcohol Dependence Symptoms Across Population-Based and Clinically Ascertained Samples. | Savage JE et al. | — | 2018 | → |
| Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. | Hasin DS et al. | — | 2017 | → |
| Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. | McClure EA et al. | — | 2017 | → |
| Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis. | Moberg CA et al. | — | 2017 | → |
| Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder. | Blanco C et al. | — | 2017 | → |
| Pragmatic trial of a Study Navigator Model (NAU) vs. Ambassador Model (N+) to increase enrollment to health research among community members who use illicit drugs. | Cottler LB et al. | — | 2017 | → |
| Toward National Estimates of Effectiveness of Treatment for Substance Use. | Blanco C et al. | — | 2017 | → |
| Grappling with the generalizability crisis in addiction treatment research. | Humphreys K | — | 2016 | → |
| Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: A systematic review on varenicline. | Motschman CA et al. | — | 2016 | → |
| Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples. | Hoertel N et al. | — | 2015 | → |
| Marijuana Use and Its Association with Participation, Navigation, and Enrollment in Health Research among African Americans. | Webb FJ et al. | — | 2015 | → |
| Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. | Dennis BB et al. | — | 2015 | → |
| Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD. | Busch AB et al. | — | 2015 | → |
| The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. | Hasin DS et al. | — | 2015 | → |
| Are participants in pharmacological and psychotherapy treatment trials for social anxiety disorder representative of patients in real-life settings? | Hoertel N et al. | — | 2014 | → |
| Implications of enrolment eligibility criteria in alcohol treatment outcome research: generalisability and potential bias in 1- and 6-year outcomes. | Storbjörk J | — | 2014 | → |
| Predictors of quit attempts and successful quit attempts among individuals with alcohol use disorders in a nationally representative sample. | Chiappetta V et al. | — | 2014 | → |
| Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample. | Hoertel N et al. | — | 2013 | → |
| Extent and reporting of patient nonenrollment in influential randomized clinical trials, 2002 to 2010. | Humphreys K et al. | — | 2013 | → |
| Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. | Rehm J et al. | — | 2013 | → |
| Prevalence of subthreshold hypomania and impact on internal validity of RCTs for major depressive disorder: results from a national epidemiological sample. | Hoertel N et al. | — | 2013 | → |
| Representativeness of patients enrolled in influential clinical trials: a comparison of substance dependence with other medical disorders. | Humphreys K et al. | — | 2013 | → |
| The evidence-based pharmacotherapy of social anxiety disorder. | Blanco C et al. | — | 2013 | → |
| The use of clinical trials in comparative effectiveness research on mental health. | Blanco C et al. | — | 2013 | → |
| Assessing adherence to guidelines for common mental disorders in routine clinical practice. | Van Fenema E et al. | — | 2012 | → |
| Assessing the Sensitivity of Treatment Effect Estimates to Differential Follow-Up Rates: Implications for Translational Research. | Griffin BA et al. | — | 2012 | → |
| Generalizability of clinical trial results for generalized anxiety disorder to community samples. | Hoertel N et al. | — | 2012 | → |
| When research meets reality-lessons learned from a pragmatic multisite group-randomized clinical trial on psychosocial interventions in the psychiatric and addiction field. | Wüsthoff LE et al. | — | 2012 | → |
| Brief interventions in dependent drinkers: a comparative prospective analysis in two hospitals. | Cobain K et al. | — | 2011 | → |
| Could a continuous measure of individual transmissible risk be useful in clinical assessment of substance use disorder? Findings from the National Epidemiological Survey on Alcohol and Related Conditions. | Ridenour TA et al. | — | 2011 | → |
| Estimating the population impact of preventive interventions from randomized trials. | Koepsell TD et al. | — | 2011 | → |
| How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. | Le Strat Y et al. | — | 2011 | → |
| Sildenafil for erectile dysfunction in the Middle East: observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting. | El-Sakka AI et al. | — | 2011 | → |
| Generalizability of clinical trials for cannabis dependence to community samples. | Okuda M et al. | — | 2010 | → |
| Subject eligibility criteria can substantially influence the results of alcohol-treatment outcome research. | Humphreys K et al. | — | 2008 | → |